The following stocks are the leading risers and fallers on AIM on Tuesday.
----------
AIM - WINNERS
----------
Trellus Health PLC, more than tripled at 2.3 pence, 12-month range 0.525p-5.1p. The London-based healthcare company announces entry into an agreement with Johnson & Johnson Health Care Systems Inc to integrate the Trellus Elevate platform into a J&J patient support programme. Johnson & Johnson Health Care Systems provides contracting, supply chain and business services to J&J’s commercial customers and intermediary partners. Trellus Elevate is a digital platform designed to help manage chronic conditions by integrating data analytics with ‘personalised, scientifically proven resilience programs and value-based solutions’. Trellus says the contract with J&J will support a pilot in the US to assess Trellus Elevate’s potential to support people with moderately to severely active inflammatory bowel disease. Company will receive an undisclosed upfront licensing fee and a fixed monthly fee for management. Eligible patients who have been prescribed a therapy from J&J will have access to Trellus Elevate. ‘We identified the pharmaceutical sector as a key strategic vertical in our September interim results and are excited to announce our first major collaboration in this vertical,’ says Chief Executive Officer Marla Dubinsky. ‘We have reached a therapeutic ceiling with many existing treatments for IBD and it is only by addressing both the mind and body that we can truly break through that barrier....By providing holistic wraparound care, we can help patients stay on track with their therapies and empower them to thrive.’
----------
MyHealthChecked PLC, up 23% at 16p, 12-month range 8.5p-16p. The Cardiff, Wales-based home testing-focused healthcare company announces that its phlebotomy test kits have been registered in the UK and EU. Says: ‘This is a key step in enabling MyHealthChecked to launch and commercialise its phlebotomy service.’ MyHealthChecked intends to commercialise the phlebotomy service in the first half of this year, offering phlebotomy test kits in addition to its existing range of test kits. Says the registration is ‘a key step in enabling MyHealthChecked to launch and commercialise its phlebotomy service’. CEO Penny McCormick says: ‘Registration of our phlebotomy tests in the UK and EU is a great achievement for the team and brings us one step closer to commercialising our phlebotomy tests. We are on track to launch our phlebotomy service in the first half of 2025 and look forward to providing an update to shareholders in due course.’
----------
AIM - LOSERS
----------
Thruvision Group PLC, down 54% at 3p, 12-month range 3p-20p. The walk-through security technology firm’s board has decided to conduct a formal strategic review, including the launch of a formal sales process. Thruvision is therefore now considered to be in an ’offer period’ as defined by the Takeover Code, and its advisors will be available for contact with parties interested in submitting a proposal. Other options being considered as part of the strategic review include seeking a strategic partner to support its growth; raising additional equity capital; and licensing its technology and intellectual property to a third party. The company notes that, as announced in late October, it ‘has significant near-term opportunities notably in Entrance Security and Retail Distribution’ with a potential contract value of around £15 million for the year ending March 31, 2026. Says it has been in ‘regular ongoing discussions’ with the potential clients, with ‘significant milestones’ scheduled for the fourth quarter of the current financial year. Adds however that it ‘does not have confirmation from these potential customers as to when purchase orders...will be entered into, if at all’. If the orders do not materialise, it expects its cash resources to last roughly until the end of May.
----------
Copyright 2025 Alliance News Ltd. All Rights Reserved.
